Top As­traZeneca I/O vet Robert Ian­none jumps to Im­munomedics as R&D chief as BLA looms

Less than a year af­ter the ac­tivist in­vestors at ven­Bio crashed a $2 bil­lion col­lab­o­ra­tion deal with Seat­tle Ge­net­ics on the lead drug at Im­munomedics $IM­MU, the new crew in charge has wooed the top I/O re­search ex­ec at As­traZeneca to take a lead­ing de­vel­op­ment role as chief med­ical of­fi­cer and R&D chief.

Robert Ian­none played a top role in the de­vel­op­ment of Imfinzi (dur­val­um­ab), the PD-L1 check­point star at As­traZeneca/Med­Im­mune. Now he’s jump­ing in­to biotech, tak­ing the lead­ing re­search role at a com­pa­ny with a mar­ket cap of $2.4 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER